COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Escitalopram and Depression in Elderly Alzheimer's Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00488670
Recruitment Status : Terminated (Dr. Rabheru left VCH last year and the study was cancelled according to his research coordinator.)
First Posted : June 20, 2007
Last Update Posted : June 6, 2011
Information provided by:
University of British Columbia

Brief Summary:
To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.

Condition or disease Intervention/treatment Phase
Depressive Disorder Drug: Escitalopram Phase 3

Detailed Description:
This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease
Study Start Date : December 2010
Actual Primary Completion Date : June 2011
Actual Study Completion Date : June 2011

Intervention Details:
  • Drug: Escitalopram
    See Detailed Description.

Primary Outcome Measures :
  1. Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.

Secondary Outcome Measures :
  1. Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • > 50 years
  • Male & female
  • Alzheimer's disease
  • Depressive episode

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00488670

Layout table for location information
Canada, British Columbia
Mt. St. Joseph's Hospital
Vancouver, British Columbia, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
Sponsors and Collaborators
University of British Columbia
Layout table for investigator information
Principal Investigator: Kiran Rabheru, MD University of British Columbia
Layout table for additonal information
Responsible Party: Dr. Kiran Rabheru, University of British Columbia Identifier: NCT00488670    
Other Study ID Numbers: H07-00050
First Posted: June 20, 2007    Key Record Dates
Last Update Posted: June 6, 2011
Last Verified: June 2011
Keywords provided by University of British Columbia:
Alzheimer's disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Mood Disorders
Mental Disorders
Behavioral Symptoms
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs